Atox Bio Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Atox Bio Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3033
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Atox Bio Ltd (Atox Bio) is a late state biotechnology company that develops immunomodulators to treat critically ill patients with severe infections. The company develops drugs for patients suffering from necrotizing soft tissue infections, a flesh eating bacteria. It implements novel mode of action into a single approach to treat severe infections by targeting the host immune system and provides solution for bacterial infections. Atox Bio’s pipeline overview includes ATB-201 and ATB-202, a Phase 3 trial, which is also known as the accute trial. The company offers peptides that provide protection from superantigen toxins and lethal bacterial infections in experimental models of a wide range of bacterial pathogens. It employs technology that targets and co-stimulates the pathway using peptides to treat several infectious and inflammatory diseases. The company has operations in Israel and the US. Atox Bio is headquartered in Ness Ziona, Israel.

Atox Bio Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Atox Bio Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Atox Bio Raises USD30 Million in Financing 10
Atox Bio Raises up to USD23 Million in Series E Venture Financing 12
Partnerships 13
Atox Bio Enters into Contract Agreement with BARDA for AB103 13
Atox Bio Ltd – Key Competitors 14
Atox Bio Ltd – Key Employees 15
Atox Bio Ltd – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Clinical Trials 17
May 29, 2018: Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI) 17
Sep 25, 2017: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections 18
May 23, 2017: Atox Bios Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Atox Bio Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Atox Bio Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Atox Bio Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Atox Bio Raises USD30 Million in Financing 10
Atox Bio Raises up to USD23 Million in Series E Venture Financing 12
Atox Bio Enters into Contract Agreement with BARDA for AB103 13
Atox Bio Ltd, Key Competitors 14
Atox Bio Ltd, Key Employees 15
Atox Bio Ltd, Other Locations 16

List of Figures
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Atox Bio Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Atox Bio Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • University of California San Diego-医療機器分野:企業M&A・提携分析
    Summary University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and h …
  • Bombardier Inc:企業の戦略・SWOT・財務情報
    Bombardier Inc - Strategy, SWOT and Corporate Finance Report Summary Bombardier Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • OMV Petrom SA (SNP):企業の財務・戦略的SWOT分析
    OMV Petrom SA (SNP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Flint Group SA:企業の戦略的SWOT分析
    Flint Group SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • PT Lotte Shopping Indonesia:企業の戦略・SWOT・財務分析
    PT Lotte Shopping Indonesia - Strategy, SWOT and Corporate Finance Report Summary PT Lotte Shopping Indonesia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Speedway Motorsports Inc (TRK):企業の財務・戦略的SWOT分析
    Summary Speedway Motorsports Inc (SMI) is a marketer, promoter and sponsor of motorsports entertainment. The company offers smaller-scale, modified racing cars and parts. It also produces and broadcasts syndicated motorsports programming to radio stations. SMI offers souvenir merchandising including …
  • American Greetings Corporation:企業の戦略・SWOT・財務情報
    American Greetings Corporation - Strategy, SWOT and Corporate Finance Report Summary American Greetings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Black River Electric Cooperative Inc:企業の戦略的SWOT分析
    Black River Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Halo Pharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary Halo Pharma Inc (Halo) is a contract development and manufacturing organization which offers scientific and development expertise services. It offers project management, formulation development and analytical development services. The organization holds specialization in the development of m …
  • Steris Corp-医療機器分野:企業M&A・提携分析
    Summary Steris Corp (Steris), formerly Innovative Medical Technologies, a subsidiary of Steris Plc, is a medical device company that offers infection prevention and other procedural products and services. The company offers surgical equipment and image management, sterile processing equipment, surgi …
  • Shanghai Pharmaceutical Co Ltd (601607)-製薬・医療分野:企業M&A・提携分析
    Summary Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. It carries out the research and development, manufacture and sale of pharmaceutical products for treating cancer, central nervous system (CNS) disorders and diseas …
  • Ambac Financial Group, Inc.:企業の戦略・SWOT・財務情報
    Ambac Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ambac Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Camlin Fine Sciences Ltd:企業の戦略・SWOT・財務情報
    Camlin Fine Sciences Ltd - Strategy, SWOT and Corporate Finance Report Summary Camlin Fine Sciences Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Jollibee Foods Corporation:企業の戦略・SWOT・財務情報
    Jollibee Foods Corporation - Strategy, SWOT and Corporate Finance Report Summary Jollibee Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • National Cancer Centre Singapore-製薬・医療分野:企業M&A・提携分析
    Summary National Cancer Centre Singapore (NCCS) is a healthcare service provider that offers research and cancer treatment services. The center offers research for cancers such as breast, gynaecology, haematology, head and neck, neuro oncology, naso pharynx cancer, paediatrics, reconstructive, hepat …
  • Moravske naftove doly AS:企業の戦略的SWOT分析
    Moravske naftove doly AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Samart Corporation Public Co Ltd (SAMART):企業の財務・戦略的SWOT分析
    Samart Corporation Public Co Ltd (SAMART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Phagelux Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Phagelux Inc (Phagelux) is an anti-infectives company that provides antibacterial products and solutions. The company uses phage lysis enzymes and biological agents for the treatment of antibiotic resistant bacteria and related diseases in human beings and crops. Its product portfolio includ …
  • G. Siempelkamp GmbH & Co KG:企業の戦略的SWOT分析
    G. Siempelkamp GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Anglo American Plc:企業のM&A・事業提携・投資動向
    Anglo American Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Anglo American Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆